Korro Bio, Inc. filings document the regulatory record of a biopharmaceutical company developing RNA-editing genetic medicines through its OPERA® platform. Its 8-K reports disclose operating and financial results, corporate presentations, clinical and regulatory program updates, capital-structure activity, and material events tied to its RNA-editing pipeline.
The company’s filings also cover proxy governance, executive compensation, equity incentive and inducement arrangements, employment agreements, and material collaboration and license agreements. Program-related disclosures focus on KRRO-121, hyperammonemia in urea cycle disorders and hepatic encephalopathy, GalNAc-conjugated oligonucleotide research, alpha-1 antitrypsin deficiency, risk factors, and the financing and governance framework supporting Korro Bio’s development-stage operations.
Korro Bio, Inc. (KRRO) reported that Lynx1 Master Fund LP purchased 79,809 shares across four transactions on October 22, October 23 and October 26, 2026. The reported weighted-average prices were $9.6764 for 12,175 shares and $11.0366 for 40,000 shares on October 22; $12.1061 for 2,510 shares on October 23; and $11.7454 for 25,124 shares on October 26.
Lynx1 Capital Management LP serves as investment manager to the fund. The reporting persons, Lynx1 Capital Management LP and Nichols Weston, are each identified as ten-percent owners and disclaim beneficial ownership except to the extent of any pecuniary interest. No Rule 10b5-1 plan is reported.
Korro Bio, Inc. reported preclinical results for KRRO-111, its candidate for the potential treatment of alpha-1 antitrypsin deficiency (AATD). In mouse and human hepatocytes, KRRO-111 showed up to 98% editing, with an EC50 of approximately 1 nM. In single-dose C57BL/6-PiZ mice, SERPINA1 editing reached up to 91%, and M-AAT made up as much as 88% of circulating AAT; both responses remained detectable through at least Day 42.
In repeat-dose NSG-PiZ mice, editing reached 96%, M-AAT comprised 93% of circulating AAT, and total AAT reached 172 μM (approximately 6-fold versus vehicle) at Day 57. In immunocompetent C57BL/6-PiZ mice, whole-liver Z-AAT was reduced 95% relative to vehicle at Day 57. Korro expects a regulatory submission for KRRO-111 in the first half of 2027.
Korro Bio, Inc. dosed the first cohort in ANCHOR, its Phase 1/2 trial of KRRO-121, administering a single 2 mg/kg dose to healthy volunteers. Part 1 includes single- and multiple-ascending-dose studies in healthy volunteers. The single-dose study started in September 2026 and is enrolling up to 30 participants across up to five cohorts; the multiple-dose study includes up to 20 participants across two cohorts.
Part 2 is designed to evaluate KRRO-121 in up to 15 people with urea cycle disorders, subject to regulatory approval. Korro expects dosing in those patients to begin in the first half of 2027, with an interim clinical readout expected in the second half of 2027. ANCHOR evaluates safety, tolerability, pharmacokinetics and clinical activity.
Korro Bio, Inc. (KRRO) reported that director Jean Francois Formela filed a Form 4 disclosing indirect sales of an aggregate 48,690 shares of common stock on September 11 and September 14, 2026, at weighted average prices around $14 per share, executed pursuant to a Rule 10b5-1 trading plan.
The transactions were carried out by investment entities Atlas Venture Fund XI, L.P. and Atlas Venture Opportunity Fund II, L.P.; Formela is a member of their general partners and disclaims Section 16 beneficial ownership of these shares except to the extent of any pecuniary interest.
Korro Bio, Inc. (KRRO) has a notice of proposed sale on file for the account of Atlas Venture Fund XI, L.P. covering up to 31,888 shares of common stock to be sold through Merrill Lynch under Rule 144. These shares were acquired in a private placement on March 23, 2023 for cash. Shares of common stock outstanding were 14,725,646 as of September 14, 2026, a baseline figure for the Rule 144 limits.
Korro Bio, Inc. (KRRO) has a Rule 144 notice indicating that Atlas Venture Opportunity Fund II, L.P. plans to sell up to 6,602 shares of Korro Bio common stock through Merrill Lynch on Nasdaq, with an approximate sale date of September 14, 2026 and an aggregate market value of $91,173.62.
The 6,602 shares were acquired in a private placement from the issuer for cash on April 22, 2024. The notice also lists multiple sales of Korro Bio common stock by Atlas Venture Fund XI, L.P. and Atlas Venture Opportunity Fund II, L.P. during the prior three months, including a trade of 101,579 shares on June 23, 2026 for $1,447,785.17.
Korro Bio, Inc. (KRRO) reported that Senior Vice President, Finance Oliver Dolan sold 5 shares of common stock on September 11, 2026 at a weighted-average price of $13.716 per share, in transactions executed under a Rule 10b5-1 trading plan adopted on June 8, 2026. Following this sale, Dolan holds 16,241 shares directly, all issuable upon settlement of unvested RSUs scheduled to vest between December 15, 2026 and July 15, 2028, subject to a continuous Service Relationship.
Korro Bio, Inc. (KRRO) has a notice of proposed resale under Rule 144 filed on behalf of Atlas Venture Fund XI, L.P. and Atlas Venture Opportunity Fund II, L.P. The filing covers the potential sale of 8,450 shares of common stock, with an aggregate market value of $110,357, relative to 14,725,646 shares outstanding as of the notice date. The shares were originally acquired in a private placement on March 23, 2023, and the proposed sales are expected to occur on or about September 11, 2026, following significant prior open-market sales by these funds in June–August 2026.
Korro Bio, Inc. (KRRO) is the issuer for which Atlas Venture Opportunity Fund II, L.P. has filed a Notice of Proposed Sale of Securities under Rule 144 covering 1,750 shares of common stock. The notice also lists multiple recent open‑market sales of Korro Bio common stock by affiliated Atlas funds.
Korro Bio, Inc. (KRRO) is the issuer for a Rule 144 notice filed on behalf of James O. Dolan for a planned sale of 5 shares of common stock, with an aggregate market value of $68.58, when 14,725,646 shares of common stock were outstanding as of September 11, 2026.